Breaking Finance News

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has been upgraded to Sell in a statement by BidaskClub earlier today.

BidaskClub has upgraded Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to Sell in a statement released on 7/08/2017.

Boasting a price of $4.89, Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) traded -0.20% lower on the day. With the last stock price close down 3.02% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the date range. Adaptimmune Therapeutics PLC – ADR has recorded a 50-day average of $5.21 and a two hundred day average of $4.96. Trade Volume was up over the average, with 242,669 shares of ADAP changing hands over the typical 224,133

Recent Performance Chart

Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC – ADR has 52 week low of $3.76 and a 52 week high of $8.36 and has a market capitalization of $0.

Brief Synopsis On Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.